Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy
Pharvaris (PHVS) reported an 83% reduction in HAE attacks with deucrictibant XR in a Phase III trial, meeting all endpoints. The company plans to submit an NDA for prophylaxis in H1 2027, following a July 2026 filing for the IR formulation. Deucrictibant targets the bradykinin B2 receptor, offering a new oral mechanism in the competitive HAE market.
How this was made
The 30-second read
Why it matters
The Phase III data positions PHVS for a potential first oral dual‑mechanism HAE therapy, differentiating it from existing kallikrein inhibitors.
Market read
Positive trial data may drive PHVS stock higher and influence the broader rare‑disease biotech sector.
What to watch
The small trial size (85 patients) may temper confidence until larger studies confirm efficacy.
Background
Pharvaris (Nasdaq: PHVS) is developing deucrictibant, a bradykinin B2 receptor antagonist for hereditary angioedema.
Ticker impact
Pharvaris reported Phase III data showing an 83% reduction in HAE attack rate for its deucrictibant XR, a first‑time disclosure.
Potential upside of 15‑20% if data leads to FDA approval expectations.
Phase III readout is material for a biotech; investors typically price in approval prospects.
Market effects
Strengthens the oral HAE therapy niche and may pressure peers like BioCryst and CSL Behring.
European and US biotech markets could see modest gains on the news.
Adds to the pipeline of innovative rare‑disease treatments, modest global relevance.
Counterpoint
If regulatory scrutiny intensifies or safety concerns emerge, the rally could be limited.
Key entities
- companyPharvaris N.V.
Biotech developer of deucrictibant.
- companyBioCryst
Competing oral HAE therapy maker.
